Debbane Raymond's Form 4 filing
Crescent Biopharma, Inc. (CBIO) · filed Aug 9, 2024
- Accession no.
- 0000950170-24-094800
- Filed
- Aug 9, 2024, 4:30 PM ET
- Trade date
- Aug 7-8, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $61.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Debbane RaymondCIK 0001053890 | 10% Owner |
| Invus Public Equities Advisors, LLCCIK 0001340096 | 10% Owner |
| Invus Public Equities, L.P.CIK 0001340097 | 10% Owner |
| Siren, L.L.C.CIK 0002005245 | 10% Owner |
| Invus Global Management, LLCCIK 0002005369 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2024 | Common Stock | SSaleDisposed | −61,488 | $0.1821 | −$11,196.96 | 6,578,438 | Direct | |
| Aug 8, 2024 | Common Stock | SSaleDisposed | −260,873 | $0.1917 | −$50,009.35 | 6,317,565 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.